American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016

Endocrine Practice

Volumn 22, Issue , 2016, Pages 1-42

  Camacho, Pauline M ^m   Petak, Steven M ^a   Binkley, Neil ^b   Clarke, Bart L ^c   Harris, Steven T ^d   Hurley, Daniel L ^c   Kleerekoper, Michael ^e   Lewiecki, E Michael ^f   Miller, Paul D ^g   Narula, Harmeet S ^h   Pessah Pollack, Rachel ⁱ   Tangpricha, Vin ^j   Wimalawansa, Sunil J ^k   Watts, Nelson B ^l  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MEDICAL COLLEGE OF OHIO   (United States)

^f NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h BANNER HEALTH   (United States)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^j EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k Prof of Medicine   (United States)

^l Mercy Health Osteoporosis and Bone Health Services   (United States)

^m NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CAFFEINE; CALCITONIN; CALCIUM; DENOSUMAB; MAGNESIUM; PARATHYROID HORMONE[1-34]; PROTEIN; RALOXIFENE; RISEDRONIC ACID; STRONTIUM; VITAMIN D; VITAMIN K GROUP; ZOLEDRONIC ACID;

ALCOHOL CONSUMPTION; ARTICLE; BODY WEIGHT; BONE DENSITOMETRY; BONE DENSITY; BONE TURNOVER; CLINICAL DECISION MAKING; CLINICAL EVALUATION; COUNSELING; DECISION MAKING; DIETARY INTAKE; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; HEALTH CARE PERSONNEL; KYPHOPLASTY; LIFESTYLE MODIFICATION; LUMBAR SPINE; MALABSORPTION; OBESITY; OSTEOLYSIS; PERCUTANEOUS VERTEBROPLASTY; PHYSICAL EXAMINATION; PHYSIOTHERAPY; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PUBLIC HEALTH; QUALITY OF LIFE; RESISTANCE TRAINING; RISK ASSESSMENT; SMOKING; SPINE FRACTURE; TREATMENT OUTCOME; VITAMIN D DEFICIENCY; ENDOCRINOLOGIST; ENDOCRINOLOGY; HUMAN; MEDICAL SOCIETY; ORGANIZATION AND MANAGEMENT; PHOTON ABSORPTIOMETRY; STANDARDS; UNITED STATES;

ABSORPTIOMETRY, PHOTON; BONE DENSITY; ENDOCRINOLOGISTS; ENDOCRINOLOGY; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; SOCIETIES, MEDICAL; UNITED STATES;

EID: 85053392470     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP161435.GL     Document Type: Article

References (321)

1. Mechanick JI, Camacho PM, Cobin RH, Garber AJ, Garber JR, Gharib H, et al. American Association of Clinical Endocrinologists Protocol for Standardized Production of Clinical Practice Guidelines-2010 update. Endocr Pract. 2010;16:270-283. [EL 4; CPG NE]
2. Mechanick JI, Camacho PM, Garber AJ, Garber JR, Pessah-Pollack R, Petak SM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Protocol for Standardized Production of Clinical Practice Guidelines, Algorithms, and Checklists-2014 Update and the AACE G4G Program. Endocr Pract. 2014;20:692-702. [EL 4; CPG NE]
3. Mechanick JI, Bergman DA, Braithwaite SS, Palumbo PJ. American Association of Clinical Endocrinologists protocol for standardized production of clinical practice guidelines. Endocr Pract. 2004;10:353-361. [EL 4; CPG NE]
4. Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29:2520-2526. [EL 3; SS]
5. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22:465-475. [EL 3; SS]
6. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137-1141. [EL 4; review NE]
7. Singer A, Exuzides A, Spangler L, O'Malley C, Colby C, Johnston K, et al. Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin Proc. 2015;90:53-62. [EL 2; RCCS]
8. Looker AC, Orwoll ES, Johnston CC Jr, Lindsay RL, Wahner HW, Dunn WL, Calvo MS, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res. 1997;12:1761-1768. [EL 3; SS]
9. Faulkner KG, von Stetten E, Miller P. Discordance in patient classification using T-scores. J Clin Densitom. 1999;2:343-350. [EL 3; SS]
10. Melton LJ 3rd, Lane AW, Cooper C, Eastell R, O'Fallon WM, Riggs BL. Prevalence and incidence of vertebral deformities. Osteoporos Int. 1993;3:113-119. [EL 3; CSS]
11. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-795. [EL 4; NE]
12. Siris ES, Adler R, Bilezikian J, Bolognese M, Dawson-Hughes B, Favus MJ, et al. The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int. 2014;25: 1439-1443. [EL 4; NE]
13. Leslie WD, Majumdar SR, Lix LM, Johansson H, Oden A, McCloskey E, et al. High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporos Int. 2012;23:391-397. [EL 2; RCCS]
14. Siris ES, Boonen S, Mitchell PJ, Bilezikian J, Silverman S. What's in a name? What constitutes the clinical diagnosis of osteoporosis? Osteoporos Int. 2012;23:2093-2097 [EL 4; review NE]
15. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-795 [EL 4; NE]
16. Guglielmi G, Muscarella S, Bazzocchi A. Integrated imaging approach to osteoporosis: state-of-the-art review and update. Radiographics. 2011;31:1343-1364. [EL 4; NE]
17. Wainwright SA, Marshall LM, Ensrud KE, Cauley JA, Black DM, Hillier TA, et al. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab. 2005;90:2787-2793. [EL 2; PCS]
18. Nayak S, Roberts MS, Chang CC, Greenspan SL. Health Beliefs about Osteoporosis and Osteoporosis Screening in Older Women and Men. Health Educ J. 2010;69:267-276. [EL 3; SS]
19. Nelson HD, Haney EM, Dana T, Bougatsos C, Chou R. Screening for osteoporosis: an update for the U.S. Preventive Services Task Force. Ann Intern Med. 2010;153: 99-111. [EL 4; CPG NE]
20. Hiligsmann M, Gathon HJ, Bruyère O, Ethgen O, Rabenda V, Reginster JY. Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health. 2010;13:394-401. [EL 3; SS]
21. Thompson M, Evitt CP, Whaley MM. Screening for falls and osteoporosis: prevention practice for the hand therapist. J Hand Ther. 2010;23:212-228; quiz 229. [EL 4; review NE]
22. Barr RJ, Stewart A, Torgerson DJ, Reid DM. Population screening for osteoporosis risk: a randomised control trial of medication use and fracture risk. Osteoporos Int. 2010;21:561-568. [EL 1; RCT; incomplete follow-up; 60% response rate]
23. Kanis JA. Assessment of osteoporosis at the primary health-care level. WHO Collaborating Center for Metabolic Bone Diseases. Technical Report. University of Sheffield, UK; 2007. Available at: https://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf. [EL 4; NE]
24. Gallagher JC, Sai AJ. Bone: Is screening for secondary causes of osteoporosis worthwhile? Nat Rev Endocrinol. 2010;6:360-362. [EL 4; opinion NE]
25. Orwig DL, Chan J, Magaziner J. Hip fracture and its consequences: differences between men and women. Orthop Clin North Am. 2006;37:611-622. [EL 4; review NE]
26. Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, et al. Interpretation and use of FRAX in clinical practice. Osteoporos Int. 2011;22:2395-2411. [EL 4; NE]
27. ®) Bone Mineral Density Task Force of the 2010 Joint International Society for Clinical Densitometry & International Osteoporosis Foundation Position Development Conference. J Clin Densitom. 2011;14:223-225. [EL 4; NE]
28. Kanis JA, Johansson H, Oden A, Cooper C, McCloskey EV; Epidemiology and Quality of Life Working Group of IOF. Worldwide uptake of FRAX. Arch Osteoporos. 2014;9:166. [EL 3; SS]
29. ®) with and without bone mineral density. Calcif Tissue Int. 2012;90:1-13. [EL 4; review NE]
30. Hillier TA, Cauley JA, Rizzo JH, Pedula KL, Ensrud KE, Bauer DC, et al. WHO absolute fracture risk models (FRAX): do clinical risk factors improve fracture prediction in older women without osteoporosis? J Bone Miner Res. 2011;26:1774-1782. [EL 2; PCS]
31. McCloskey E, Kanis JA. FRAX updates 2012. Curr Opin Rheumatol. 2012;24:554-560. [EL 4; review NE]
32. Silverman SL, Calderon AD. The utility and limitations of FRAX: A US perspective. Curr Osteoporos Rep. 2010; 8:192-197. [EL 4; review NE]
33. Watts NB, Ettinger B, LeBoff MS. FRAX facts. J Bone Miner Res. 2009;24:975-979. [EL 4; NE]
34. van den Bergh JP, van Geel TA, Lems WF, Geusens PP. Assessment of individual fracture risk: FRAX and beyond. Curr Osteoporos Rep. 2010;8:131-137. [EL 4; review NE]
35. Kreidieh OI, El-Hajj Fuleihan G. Impact of changes in mortality on FRAX-derived fracture probabilities. Bone. 2014;62:43-50 [EL 3; CSS]
36. Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22:809-816. [EL 2; PCS]
37. Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA. Spine-hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement. Osteoporos Int. 2011;22:839-847. [EL 2; RCCS]
38. Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA, et al. Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Miner Res. 2012;27:1243-1251. [EL 3; CSS]
39. Sambrook PN, Cameron ID, Chen JS, Cumming RG, Lord SR, March LM, et al. Influence of fall related factors and bone strength on fracture risk in the frail elderly. Osteoporos Int. 2007;18:603-610. [EL 2; PCS]
40. Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18:1033-1046. [EL 2; MNRCT]
41. International Society for Clinical Densitometry. 2015 ISCD Official Positions − Adult. Middletown, CT: International Society for Clinical Densitometry; 2015. [EL 4; position statement]
42. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20:1185-1194. [EL 2; PCS]
43. Stone KL, Seeley DG, Lui LY, Cauley JA, Ensrud K, Browner WS, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res. 2003;18: 1947-1954. [EL 2; PCS]
44. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet. 1993;341:72-75. [EL 2; PCS]
45. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254-1259 [EL 2; MNRCT]
46. Austin M, Yang YC, Vittinghoff E, Adami S, Boonen S, Bauer DC, et al. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res. 2012;27:687-693. [EL 1; RCT]
47. Barzel US. Recommended testing in patients with low bone density. J Clin Endocrinol Metab. 2003;88:1404-1405; author reply 1405. [EL 4; opinion NE]
48. Tannenbaum C, Clark J, Schwartzman K, Wallenstein S, Lapinski R, Meier D, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab. 2002;87: 4431-4437. [EL 3; CSS]
49. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285:320-323. [EL 1; MRCT]
50. Gehlbach S, Saag KG, Adachi JD, Hooven FH, Flahive J, Boonen S, et al. Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res. 2012;27:645-653. [EL 3; SS]
51. Edwards BJ, Bunta AD, Simonelli C, Bolander M, Fitzpatrick LA. Prior fractures are common in patients with subsequent hip fractures. Clin Orthop Relat Res. 2007;461:226-230. [EL 2; RCCS]
52. Camacho PM, Dayal AS, Diaz JL, Nabhan FA, Agarwal M, Norton JG, et al. Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis. J Clin Oncol. 2008;26:5380-5385. [EL 2; RCCS]
53. Lane NE. An update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am. 2001;27:235-253. [EL 4; opinion NE]
54. Lewiecki EM, Laster AJ. Clinical review: Clinical applications of vertebral fracture assessment by dual-energy x-ray absorptiometry. J Clin Endocrinol Metab. 2006;91: 4215-4222. [EL 4; review NE]
55. Greenspan SL, von Stetten E, Emond SK, Jones L, Parker RA. Instant vertebral assessment: a noninvasive dual X-ray absorptiometry technique to avoid misclassifi-cation and clinical mismanagement of osteoporosis. J Clin Densitom. 2001;4:373-380. [EL 3; CSS]
56. Schousboe JT, Debold CR. Reliability and accuracy of vertebral fracture assessment with densitometry compared to radiography in clinical practice. Osteoporos Int. 2006; 17:281-289. [EL 3; CSS]
57. Binkley N, Krueger D, Gangnon R, Genant HK, Drezner MK. Lateral vertebral assessment: a valuable technique to detect clinically significant vertebral fractures. Osteoporos Int. 2005;16:1513-1518. [EL 3; CSS]
58. Siminoski K, Jiang G, Adachi JD, Hanley DA, Cline G, Ioannidis G, et al. Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures. Osteoporos Int. 2005;16:403-410. [EL 2; PCS]
59. Siminoski K, Warshawski RS, Jen H, Lee K. The accuracy of historical height loss for the detection of vertebral fractures in postmenopausal women. Osteoporos Int. 2006; 17:290-296. [EL 3; CSS]
60. Chesnut CH 3rd, Bell NH, Clark GS, Drinkwater BL, English SC, Johnson CC Jr, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med. 1997;102:29-37. [EL 1; RCT, no blinding]
61. Ross PD, Knowlton W. Rapid bone loss is associated with increased levels of biochemical markers. J Bone Miner Res. 1998;13:297-302. [EL 2; PCS]
62. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res. 1999;14:1614-1621. [EL 2; PCS]
63. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res. 1996;11:1531-1538. [EL 2; PCS]
64. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res. 2000;15:1526-1536. [EL 2; PCS]
65. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003;18:1051-1056. [EL 1; RCT]
66. Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22:391-420. [EL 2; MNRCT]
67. Bauer D, Krege J, Lane N, Leary E, Libanati C, Miller P, et al. National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int. 2012;23:2425-2433. [EL 4; consensus NE]
68. Greenspan SL, Resnick NM, Parker RA. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab. 2005;90:2762-2767. [EL 1; RCT]
69. Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2006;91:1370-1375. [EL 1; RCT]
70. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002;87:1586-1592. [EL 1; MRCT]
71. Bauer DC, Schwartz A, Palermo L, Cauley J, Hochberg M, Santora A, et al. Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Int Med. 2014;174:1126-1134. [EL 1; RCT]
72. Eastell R, Vrijens B, Cahall DL, Ringe JD, Garnero P, Watts NB. Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence. J Bone Miner Res. 2011;26:1662-1669. [EL 2; PCS]
73. Delmas PD, Munoz F, Black DM, Cosman F, Boonen S, Watts NB, et al. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Min Res. 2009;24:1544-1551. [EL 1; RCT]
74. Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res. 2011;26:530-537 [EL 1; RCT]
75. Carmel AS, Shieh A, Bang H, Bockman RS. The 25(OH) D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. Osteoporos Int. 2012;23:2479-2487. [EL 2; PCS]
76. Bischoff-Ferrari HA, Dietrich T, Orav EJ, Dawson-Hughes B. Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am J Med. 2004;116: 634-639. [EL 3; CSS]
77. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. T J Clin Endocrinol Metab. 2011;96:53-58. [EL 4; consensus NE]
78. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96:1911-1930. [EL 4; consensus NE]
79. Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT, et al. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab. 2005;90: 3215-3224. [EL 3; CSS]
80. LeBoff MS, Hawkes WG, Glowacki J, Yu-Yahiro J, Hurwitz S, Magaziner J. Vitamin D-deficiency and post-fracture changes in lower extremity function and falls in women with hip fractures. Osteoporos Int. 2008;19:1283-1290. [EL 2; PCS]
81. Wimalawansa SJ. Vitamin D in the new millennium. Curr Osteoporos Rep. 2012;10:4-15. [EL 4; review NE]
82. Baron JA, Barry EL, Mott LA, Rees JR, Sandler RS, Snover DC, et al. A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. N Engl J Med. 2015;373:1519-1530. [EL 1; RCT]
83. Arora P, Song Y, Dusek J, Plotnikoff G, Sabatine MS, Cheng S, et al. Vitamin D therapy in individuals with prehypertension or hypertension: the DAYLIGHT trial. Circulation. 2015;131:254-262. [EL 1; RCT]
84. Mason C, Xiao L, Imayama I, Duggan C, Wang CY, Korde L, et al. Vitamin D3 supplementation during weight loss: a double-blind randomized controlled trial. Am J Clin Nutr. 2014;99:1015-1025. [EL 1; RCT]
85. Dhaliwal R, Mikhail M, Feuerman M, Aloia JF 2014 The vitamin d dose response in obesity. Endocr Pract. 20: 1258-1264. [EL 1; RCT]
86. Ng K, Scott JB, Drake BF, Chan AT, Hollis BW, Chandler PD, et al. Dose response to vitamin D supplementation in African Americans: results of a 4-arm, randomized, placebo-controlled trial. Am J Clin Nutr. 2014;99:587-598. [EL 1; RCT]
87. Knutsen KV, Madar AA, Lagerlov P, Brekke M, Raastad T, Stene LC, et al. Does vitamin D improve muscle strength in adults? A randomized, double-blind, placebo-controlled trial among ethnic minorities in Norway. J Clin Endocrinol Metab. 2014;99:194-202. [EL 1; RCT]
88. Chaney A, Heckman MG, Diehl NN, Meek S, Keaveny AP 2015 Effectiveness and Outcomes of Current Practice in Treating Vitamin D Deficiency in Patients Listed for Liver Transplantation. Endocr Pract. 21:761-769. [EL 2; retrospective analysis]
89. Farahati J, Nagarajah J, Gilman E, Mahjoob S, Zohreh M, Rosenbaum-Krumme S, et al. Ethnicity, Clothing Style, and Body Mass Index are Significant Predictors of Vitamin D Insufficiency in Germany. Endocr Pract. 2015; 21:122-127. [EL 2; retrospective analysis]
90. Li Y, Chen C, Liu HL, Qian G. Vitamin D, parathyroid hormone, and heart failure in a chinese elderly population. Endocr Pract. 2015;21:30-40. [EL 2; PCS]
91. Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997;7:439-443. [EL 3; CSS]
92. Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P. Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab. 2007;92:1415-1423. [EL 1; MRCT]
93. Hansen KE, Johnson RE, Chambers KR, Johnson MG, Lemon CC, Vo TN, et al. Treatment of Vitamin D Insufficiency in Postmenopausal Women: A Randomized Clinical Trial. JAMA Int Med. 2015;175:1612-1621. [EL 1; RCT]
94. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005;293:2257-2264. [EL 1; MRCT]
95. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006; 354:669-683. [EL 1; RCT]
96. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, et al. Effect of Vitamin D on falls: a meta-analysis. JAMA. 2004;291:1999-2006. [EL 2; MNRCT]
97. Bischoff-Ferrari HA, Conzelmann M, Stähelin HB, Dick W, Carpenter MG, Adkin AL, et al. Is fall prevention by vitamin D mediated by a change in postural or dynamic balance? Osteoporos Int. 2006;17:656-663. [EL 1; RCT]
98. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res. 2000;15:1113-1118. [EL 1; RCT]
99. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med. 2007;167:1730-1737. [EL 1; MRCT]
100. Kearns MD, Alvarez JA, Tangpricha V 2014 Large, single-dose, oral vitamin d supplementation in adult populations: a systematic review. Endocr Pract. 20:341-351. [EL 2; MNRCT]
101. Weaver CM, Alexander DD, Boushey CJ, Dawson-Hughes B, Lappe JM, LeBoff MS, et al. Calcium plus vitamin D supplementation and risk of fractures: an updated meta-analysis from the National Osteoporosis Foundation. Osteoporos Int. 2016;27:367-376. [EL 1; MRCT]
102. Porthouse J, Cockayne S, King C, Saxon L, Steele E, Aspray T, et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. BMJ. 2005;330: 1003. [EL 1; RCT]
103. Shea B, Wells G, Cranney A, Zytaruk N, Robinson V, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr Rev. 2002;23:552-559. [EL 1; MRCT]
104. Grant AM, Avenell A, Campbell MK, McDonald AM, MacLennan GS, McPherson GC, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet. 2005;365:1621-1628. [EL 1; RCT]
105. Michaelsson K, Melhus H, Warensjo Lemming E, Wolk A, Byberg L. Long term calcium intake and rates of all cause and cardiovascular mortality: community based prospective longitudinal cohort study. BMJ. 2013;346:f228. [EL 2; PCS]
106. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ. 2011;342:d2040. [EL 1; RCT]
107. Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010; 341:c3691. [EL 1; RCT]
108. Bolland MJ, Barber PA, Doughty RN, Mason B, Horne A, Ames R, et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ. 2008;336:262-266. [EL 1; RCT]
109. Bostick RM, Kushi LH, Wu Y, Meyer KA, Sellers TA, Folsom AR. Relation of calcium, vitamin D, and dairy food intake to ischemic heart disease mortality among postmenopausal women. Am J Epidemiol. 1999;149:151-161. [EL 2; PCS]
110. Zhu K, Bruce D, Austin N, Devine A, Ebeling PR, Prince RL. Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency. J Bone Miner Res. 2008;23:1343-1348. [EL 1; RCT]
111. Zhu K, Devine A, Dick IM, Wilson SG, Prince RL. Effects of calcium and vitamin D supplementation on hip bone mineral density and calcium-related analytes in elderly ambulatory Australian women: a five-year randomized controlled trial. J Clin Endocrinol Metab. 2008;93: 743-749. [EL 1; RCT]
112. Langsetmo L, Berger C, Kreiger N, Kovacs CS, Hanley DA, Jamal SA, et al. Calcium and vitamin D intake and mortality: results from the Canadian Multicentre Osteoporosis Study (CaMos). J Clin Endocrinol Metab. 2013;98:3010-3018. [EL 2; PCS]
113. Silverman SL, Cummings SR, Watts NB, Consensus Panel of the ASBMR, ISCD, and NOF. Recommendations for the clinical evaluation of agents for treatment of osteoporosis: consensus of an expert panel representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF). J Bone Min Res. 2008;23:159-165. [EL 4; consensus NE]
114. Bauer DC. Clinical practice. Calcium supplements and fracture prevention. N Engl J Med. 2013;369:1537-1543. [EL 4; review NE]
115. Prentice RL, Pettinger MB, Jackson RD, Wactawski-Wende J, Lacroix AZ, Anderson GL, et al. Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study. Osteoporos Int. 2013;24:567-580. [EL 1; RCT]
116. Reid IR, Bolland MJ. Calcium supplements: bad for the heart? Heart. 2012;98:895-896. [EL 4; NE]
117. Bolland MJ, Grey A, Gamble GD, Reid IR. Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set. Am J Clin Nutr. 2011;94:1144-1149. [EL 1; RCT]
118. Moyer VA; U.S. Preventive Services Task Force. Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;158:691-696. [EL 4; consensus NE]
119. Ross AC. The 2011 report on dietary reference intakes for calcium and vitamin D. Public Health Nutr. 2011;14:938-939. [EL 4; NE]
120. Alaimo K, McDowell MA, Briefel RR, Bischof AM, Caughman CR, Loria CM, et al. Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, Phase 1, 1988-91. Adv Data. 1994;1-28. [EL 3; SS]
121. Kim MH, Kim EJ, Jung JY, Choi MK. Effect of water-soluble silicon supplementation on bone status and balance of calcium and magnesium in male mice. Biol Trace Elem Res. 2014;158:238-242. [EL 4; NE]
122. Spencer H, Fuller H, Norris C, Williams D. Effect of magnesium on the intestinal absorption of calcium in man. J Am Coll Nutr. 1994;13:485-492. [EL 3; CCS]
123. Jackson HA, Sheehan AH. Effect of vitamin A on fracture risk. Ann Pharmacother. 2005;39:2086-2090 [EL 4; review NE]
124. Braam LA, Knapen MH, Geusens P, Brouns F, Hamulyak K, Gerichhausen MJ, et al. Vitamin K1 supplementation retards bone loss in postmenopausal women between 50 and 60 years of age. Calcif Tissue Int. 2003; 73:21-26. [EL 1; RCT]
125. Alexandersen P, Toussaint A, Christiansen C, Devogelaer JP, Roux C, Fechtenbaum J, et al. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA. 2001;285:1482-1488. [EL 1; RCT]
126. Atkinson C, Compston JE, Day NE, Dowsett M, Bingham SA. The effects of phytoestrogen isoflavones on bone density in women: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2004;79:326-333. [EL 1; RCT]
127. Gallagher JC, Satpathy R, Rafferty K, Haynatzka V. The effect of soy protein isolate on bone metabolism. Menopause. 2004;11:290-298. [EL 1; RCT, small sample size, no placebo]
128. Hallström H, Wolk A, Glynn A, Michaëlsson K. Coffee, tea and caffeine consumption in relation to osteoporotic fracture risk in a cohort of Swedish women. Osteoporos Int. 2006;17:1055-1064. [EL 2; PCS]
129. Kiel DP, Felson DT, Hannan MT, Anderson JJ, Wilson PW. Caffeine and the risk of hip fracture: the Framingham Study. Am J Epidemiol. 1990;132:675-684. [EL 2; PCS]
130. Barrett-Connor E, Chang JC, Edelstein SL. Coffee-associated osteoporosis offset by daily milk consumption. The Rancho Bernardo Study. JAMA. 1994;271:280-283. [EL 2; NRCT]
131. Rizzoli R, Ammann P, Chevalley T, Bonjour JP. Protein intake and bone disorders in the elderly. Joint Bone Spine. 2001;68:383-392. [EL 4; review NE]
132. Schurch MA, Rizzoli R, Slosman D, Vadas L, Vergnaud P, Bonjour JP. Protein supplements increase serum insulin-like growth factor-I levels and attenuate proximal femur bone loss in patients with recent hip fracture. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:801-809. [EL 1; RCT, small sample size]
133. Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman JA, et al. Alcohol intake as a risk factor for fracture. Osteoporos Int. 2005;16:737-742. [EL 2; PCS]
134. Giampietro PF, McCarty C, Mukesh B, McKiernan F, Wilson D, Shuldiner A, et al. The role of cigarette smoking and statins in the development of postmenopausal osteoporosis: a pilot study utilizing the Marshfield Clinic Personalized Medicine Cohort. Osteoporos Int. 2010;21: 467-477. [EL 2; CCS]
135. Daniell HW. Osteoporosis of the slender smoker. Vertebral compression fractures and loss of metacarpal cortex in relation to postmenopausal cigarette smoking and lack of obesity. Arch Intern Med. 1976;136:298-304. [EL 3; CSS]
136. Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int. 2005;16:155-162. [EL 2; MNRCT]
137. Kelley GA, Kelley KS, Tran ZV. Exercise and lumbar spine bone mineral density in postmenopausal women: a meta-analysis of individual patient data. J Gerontol A Biol Sci Med Sci. 2002;57:M599-M604. [EL 2; MNRCT]
138. Gardner MM, Phty M, Robertson MC, McGee R, Campbell AJ. Application of a falls prevention program for older people to primary health care practice. Prev Med. 2002;34:546-553. [EL 2; PCS]
139. Robertson MC, Campbell AJ, Gardner MM, Devlin N. Preventing injuries in older people by preventing falls: a meta-analysis of individual-level data. J Am Geriatr Soc. 2002;50:905-911. [EL 2; MNRCT]
140. Wolff I, van Croonenborg JJ, Kemper HC, Kostense PJ, Twisk JW. The effect of exercise training programs on bone mass: a meta-analysis of published controlled trials in pre- and postmenopausal women. Osteoporos Int. 1999;9: 1-12. [EL 2; MNRCT]
141. Choi M, Hector M. Effectiveness of intervention programs in preventing falls: a systematic review of recent 10 years and meta-analysis. J Am Med Dir Assoc. 2012;13:188 e113-e121. [EL 1; MRCT]
142. Sherrington C, Whitney JC, Lord SR, Herbert RD, Cumming RG, Close JC. Effective exercise for the prevention of falls: a systematic review and meta-analysis. J Am Geriatr Soc. 2008;56:2234-2243. [EL 1; MRCT]
143. Kelley GA, Kelley KS, Kohrt WM. Effects of ground and joint reaction force exercise on lumbar spine and femoral neck bone mineral density in postmenopausal women: a meta-analysis of randomized controlled trials. BMC Musculoskelet Disord. 2012;13:177. [EL 1; MRCT]
144. Scott V, Wagar L, Elliott S. Falls & related injuries among older Canadians: Fall-related hospitalizations & intervention initiatives. Dvision of Aging and Seniors, Public Health Agency of Canada; 2010. Available at: http://www.hiphealth.ca/media/research_cemfia_phac_epi_and_inventor_20100610.pdf. [EL 4; NE]
145. Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson LM, et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev. 2012;9:CD007146. [EL 1; MRCT]
146. Granacher U, Gollhofer A, Hortobagyi T, Kressig RW, Muehlbauer T. The importance of trunk muscle strength for balance, functional performance, and fall prevention in seniors: a systematic review. Sports Med. 2013;43:627-641. [EL 2; MNRCT]
147. Tinetti ME, Speechley M, Giner SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988;319:1701-1707. [EL 2; PCS]
148. Hausdorff JM, Rios DA, Edelberg HK. Gait variability and fall risk in community-living older adults: a 1-year prospective study. Arch Phys Med Rehabil. 2001;82:1050-1056. [EL 2; PCS]
149. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Web-based Injury Statistics Query and Reporting System (WISQARS). Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2006. Available at: https://www.cdc.gov/injury/wisqars/. [EL 4; NE]
150. Stevens JA RG, Kresnow MS. Fatalities and injuries from falls among older adults-United States, 1993-2003 and 2001-2005. MMWR Morb Mortal Wkly Rep. 2006;55: 1221-1224. [EL 3; SS]
151. da Silva RB, Costa-Paiva L, Morais SS, Mezzalira R, Ferreira Nde O, Pinto-Neto AM. Predictors of falls in women with and without osteoporosis. J Orthop Sports Phys Ther. 2010;40:582-588. [EL 3; CSS]
152. Blain H, Rolland Y, Beauchet O, Annweiler C, Benhamou CL, Benetos A, et al. Usefulness of bone density measurement in fallers. Joint Bone Spine. 2014;5:403-408. [EL 4; NE]
153. Briot K, Cortet B, Thomas T, Audran M, Blain H, Breuil V, et al. 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine. 2012; 79:304-313. [EL 4; consensus, NE]
154. van Doorn C, Gruber-Baldini AL, Zimmerman S, Hebel JR, Port CL, Baumgarten M, et al. Dementia as a risk factor for falls and fall injuries among nursing home residents. J Am Geriatr Soc. 2003;51:1213-1218. [EL 2; PCS]
155. Goodwin VA, Abbott RA, Whear R, Bethel A, Ukoumunne OC, Thompson-Coon J, et al. Multiple component interventions for preventing falls and fall-related injuries among older people: systematic review and meta-analysis. BMC Geriatr. 2014;14:15. [EL 1; MRCT]
156. Kemmler W, Haberle L, von Stengel S. Effects of exercise on fracture reduction in older adults: a systematic review and meta-analysis. Osteoporos Int. 2013;24:1937-1950. [EL 2; MNRCT]
157. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, Orav JE, Stuck AE, Theiler R, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ. 2009;339:b3692. [EL 1; MRCT]
158. Uusi-Rasi K, Patil R, Karinkanta S, Kannus P, Tokola K, Lamberg-Allardt C, et al. Exercise and vitamin D in fall prevention among older women: a randomized clinical trial. JAMA Int Med. 2015;175:703-711. [EL 1; RCT]
159. Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, et al. Annual high-dose oral vitamin D and falls and fractures in older women. JAMA. 2010;303:1815-1822. [EL 1; RCT]
160. Parker MJ, Gillespie WJ, Gillespie LD. Effectiveness of hip protectors for preventing hip fractures in elderly people: systematic review. BMJ. 2006;332:571-574. [EL 2; MNRCT, quasi-randomized included]
161. Sawka AM, Boulos P, Beattie K, Thabane L, Papaioannou A, Gafni A, et al. Do hip protectors decrease the risk of hip fracture in institutional and community-dwelling elderly? A systematic review and meta-analysis of randomized controlled trials. Osteoporos Int. 2005;16: 1461-1474. [EL 1; MRCT]
162. Singh S, Sun H, Anis AH. Cost-effectiveness of hip protectors in the prevention of osteoporosis related hip fractures in elderly nursing home residents. J Rheumatol. 2004;31:1607-1613. [EL 3; SS]
163. van Schoor NM, Asma G, Smit JH, Bouter LM, Lips P. The Amsterdam Hip Protector Study: compliance and determinants of compliance. Osteoporos Int. 2003;14:353-359. [EL 2; PCS]
164. Warnke A, Meyer G, Bender R, Muhlhauser I. Predictors of adherence to the use of hip protectors in nursing home residents. J Am Geriatr Soc. 2004;52:340-345. [EL 2; RCCS]
165. Kiel DP, Magaziner J, Zimmerman S, Ball L, Barton BA, Brown KM, et al. Efficacy of a hip protector to prevent hip fracture in nursing home residents: the HIP PRO randomized controlled trial. JAMA. 2007;298:413-422. [EL 2; MNRCT, quasi-randomized included]
166. Santesso N, Carrasco-Labra A, Brignardello-Petersen R. Hip protectors for preventing hip fractures in older people. Cochrane Database Syst Rev. 2014;3:CD001255. [EL 2; MNRCT, quasi-randomized included]
167. Gillespie WJ, Gillespie LD, Parker MJ. Hip protectors for preventing hip fractures in older people. Cochrane Database Syst Rev. 2010;CD001255. [EL 2; MRCT, quasi-RCTs included]
168. Wei QS, Huang L, Chen XH, Wang HB, Sun WS, Huo SC, et al. Effect of whole body vibration therapy on circulating serotonin levels in an ovariectomized rat model of osteoporosis. Iran J Basic Med Sci. 2014;17:62-68. [EL 4; NE]
169. Totosy de Zepetnek JO, Giangregorio LM, Craven BC. Whole-body vibration as potential intervention for people with low bone mineral density and osteoporosis: a review. J Rehabil Res Dev. 2009;46:529-542. [EL 4; review NE]
170. Ruan XY, Jin FY, Liu YL, Peng ZL, Sun YG. Effects of vibration therapy on bone mineral density in postmenopausal women with osteoporosis. Chinese Med J (Engl). 2008;121:1155-1158. [EL 2; NRCT]
171. Li WC, Chen YC, Yang RS, Tsauo JY. Effects of exercise programmes on quality of life in osteoporotic and osteopenic postmenopausal women: a systematic review and meta-analysis. Clin Rehabil. 2009;23:888-896. [EL 1; MRCT]
172. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-1541. [EL 1; RCT]
173. Chesnut IC, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19: 1241-1249. [EL 1; RCT]
174. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344-1352. [EL 1; RCT]
175. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11:83-91. [EL 1; RCT]
176. Kanis JA, Barton IP, Johnell O. Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporos Int. 2005;16:475-482. [EL 1; RCT]
177. Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000;109:267-276. [EL 1; RCT]
178. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-645. [EL 1; RCT]
179. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-765. [EL 1; RCT]
180. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344:1434-1441. [EL 1; RCT, partial blinding]
181. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture. N Engl J Med. 2007;357:nihpa40967. [EL 1; RCT]
182. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85:4118-4124. [EL 2; PCS]
183. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927-2938. [EL 1; RCT]
184. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189-1199. [EL 4; NE]
185. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005;20:1315-1322. [EL 1; RCT]
186. Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2006;65:654-661. [EL 1; RCT]
187. Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol. 2008; 35:488-497. [EL 1; RCT]
188. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333-340. [EL 1; RCT]
189. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-1822. [EL 1; RCT]
190. Sorensen OH, Crawford GM, Mulder H, Hosking DJ, Gennari C, Mellstrom D, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone. 2003;32:120-126. [EL 1; RCT]
191. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333. [EL 1; RCT]
192. Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, Baim S, Favus MJ, Khosla S, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int. 2008;19:449-458. [EL 4; opinion NE]
193. Guideline for the prevention of falls in older persons. American Geriatrics Society, British Geriatrics Society, and American Academy of Orthopaedic Surgeons Panel on Falls Prevention. J Am Geriatr Soc. 2001;49:664-672. [EL 4; guideline]
194. Kanis JA, Johansson H, Oden A, Dawson-Hughes B, Melton LJ 3rd, McCloskey EV. The effects of a FRAX revision for the USA. Osteoporos Int. 2010;21:35-40. [EL 3; SS]
195. Ettinger B, Black DM, Dawson-Hughes B, Pressman AR, Melton LJ 3rd. Updated fracture incidence rates for the US version of FRAX. Osteoporos Int. 2010;21:25-33. [EL 3; SS]
196. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int. 2008;19:437-447. [EL 3; CSS]
197. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082. [EL 1; RCT]
198. Watts NB, Roux C, Modlin JF, Brown JP, Daniels A, Jackson S, et al. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? Osteoporos Int. 2012; 23:327-337. [EL 1; RCT]
199. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93:2149-2157. [EL 1; RCT]
200. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43:222-229. [EL 1; RCT]
201. McClung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int. 2013;24:227-235. [EL 1; RCT]
202. Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab. 2013;98:4483-4492. [EL 1; RCT]
203. Watts NB, Miller PD, Kohlmeier LA, Sebba A, Chen P, Wong M, et al. Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment. J Bone Miner Res. 2009;24:1125-1131. [EL 2; RCCS]
204. McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH 3rd, Ensrud KE, et al. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res. 2004;19:11-18. [EL 1; RCT]
205. 2015 Atelvia (risedronate sodium) delayed-release tablets. In. North Norwich, NY: Norwich Pharmaceuticals, Inc. [EL 4; NE]
206. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Intl Suppl. 2009;S1-S130. [EL 4; CPG NE]
207. Jones SG, Dolan G, Lengyel K, Myers B. Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions. Br J Haematol. 2002;119:576-577. [EL 4; NE]
208. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med. 2003;349:1676-1679; discussion 1676-1679. [EL 3; SS]
209. Tarassoff P HY, Maladorno D. Renal failure with the use of zoledronic acid. N Engl J Med. 2003;349:1678-1679. [EL 4; NE]
210. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int. 1987;41:326-331. [EL 2; PCS]
211. Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med. 2005;165:346-347. [EL 3; SS]
212. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA. 2010;304:657-663. [EL 2; PCS]
213. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ. 2010;341:c4444. [EL 2; RCCS]
214. McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013;126: 13-20. [EL 4; review NE]
215. U.S. Food & Drug Administration. Questions and answers: changes to the indicated population for miaclcin (calcitonin-salmon). U.S. Food & Drug Administration; 2014. Available at: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ ucm388641.htm [EL 4; NE]
216. 2011 Evista (raloxifene hydrochloride) Tablet for Oral Use [package insert]. Indianapolis, IN: Eli Lilly and Company. [EL 4, NE]
217. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641-1647. [EL 1; RCT]
218. Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res. 2005;20:1514-1524. [EL 1; RCT]
219. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006; 295:2727-2741. [EL 1; RCT]
220. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125-137. [EL 1; RCT]
221. 2014 Fortical (calcitonin-salmon [rDNA origin]) Nasal Spray for intranasal use [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, Inc. [EL 4; NE]
222. 2014 Miacalcin (calcitonin-salmon) for injection and nasal spray [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. [EL 4; NE]
223. Pun KK, Chan LW. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther. 1989;11:205-209. [EL 2; NRCT]
224. Ofluoglu D, Akyuz G, Unay O, Kayhan O. The effect of calcitonin on beta-endorphin levels in postmenopausal osteoporotic patients with back pain. Clin Rheumatol. 2007;26:44-49. [EL 1; RCT, small sample]
225. Laroche M, Cantogrel S, Jamard B, Constantin A, Zabraniecki L, Cantagrel A, et al. Comparison of the analgesic efficacy of pamidronate and synthetic human calcitonin in osteoporotic vertebral fractures: a double-blind controlled study. Clin Rheumatol. 2006;25:683-686. [EL 1; RCT, no placebo, small sample]
226. Lyritis GP, Ioannidis GV, Karachalios T, Roidis N, Kataxaki E, Papaioannou N, et al. Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study. Clin J Pain. 1999;15:284-289. [EL 1; RCT, small sample]
227. Lyritis GP, Paspati I, Karachalios T, Ioakimidis D, Skarantavos G, Lyritis PG. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. Acta Orthop Scand Suppl. 1997;275:112-114. [EL 1; RCT]
228. 2014 Premarin (conjugated estrogens) Tablets, USP for oral use [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc. [EL 4; NE]
229. Pinkerton JV, Harvey JA, Lindsay R, Pan K, Chines AA, Mirkin S, et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab. 2014;99:E189-E198. [EL 1; RCT]
230. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003;290:1729-1738. [EL 1; RCT]
231. Jackson RD, Wactawski-Wende J, LaCroix AZ, Pettinger M, Yood RA, Watts NB, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. J Bone Miner Res. 2006;21:817-828. [EL 1; RCT]
232. 2012 Forteo (teriparatide [rDNA origin] injection) for subcutaneous use [package insert]. Indianapolis, IN: Eli Lilly and Company. [EL 4; NE]
233. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002;30:312-321. [EL 4; NE]
234. Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol. 2004;32:426-438. [EL 4; NE]
235. Harper KD, Krege JH, Marcus R, Mitlak BH. Osteosarcoma and teriparatide? J Bone Miner Res. 2007; 22:334. [EL 4; NE]
236. Subbiah V, Madsen VS, Raymond AK, Benjamin RS, Ludwig JA. Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int. 2010;21:1041-1045. [EL 3; SCR]
237. Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004; 164:2024-2030. [EL 2; PCS]
238. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, et al. One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005;353:555-565. [EL 1; RCT]
239. Reginster JY. Cardiac concerns associated with strontium ranelate. Expert Opin Drug Saf. 2014;13:1209-1213. [EL 4; NE]
240. European Medicines Agency. 2013 Assessment report-periodic safety update report. London, UK: European Medicines Agency; 2013. EPAR - Protelos-H-C-560-PSU31. [EL 3; SS]
241. Audran M, Jakob FJ, Palacios S, Brandi ML, Broll H, Hamdy NA, et al. A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years. Rheumatol Int. 2013;33:2231-2239. [EL 2; PCS]
242. Cooper C, Fox KM, Borer JS. 2014 Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD. Osteoporos Int. 2014;25:737-745. [EL 2; RCCS]
243. Abrahamsen B, Grove EL, Vestergaard P. Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. Osteoporos Int. 2014;25:757-762. [EL 3; SS]
244. Svanström H, Pasternak B, Hviid A. Use of strontium ranelate and risk of acute coronary syndrome: cohort study. Ann Rheum Dis. 2014;73:1037-1043. [EL 3; SS]
245. Blake GM, Fogelman I. The correction of BMD measurements for bone strontium content. J Clin Densitom. 2007; 10:259-265. [EL 4; NE]
246. Greenspan SL, Maitland LA, Myers ER, Krasnow MB, Kido TH. Femoral bone loss progresses with age: a longitudinal study in women over age 65. J Bone Miner Res. 1994;9:1959-1965. [EL 2; PCS, small sample size]
247. Finkelstein JS, Brockwell SE, Mehta V, Greendale GA, Sowers MR, Ettinger B, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab. 2008;93:861-868. [EL 2; PCS]
248. Gourlay ML, Fine JP, Preisser JS, May RC, Li C, Lui LY, et al. Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med. 2012;366:225-233. [EL 2; PCS]
249. Lewiecki EM, Watts NB. Assessing response to osteoporosis therapy. Osteoporos Int. 2008;19:1363-1368. [EL 4; review NE]
250. Lewiecki EM, Randolph LA. How common is loss of bone mineral density in elderly clinical practice patients receiving oral bisphosphonate therapy for osteoporosis? J Bone Miner Res. 2002;17:S367. [EL 4; NE]
251. Lenchik L, Kiebzak GM, Blunt BA. What is the role of serial bone mineral density measurements in patient management? J Clin Densitom. 2002;5 Suppl:S29-S38. [EL 4; NE]
252. Baim S, Wilson CR, Lewiecki EM, Luckey MM, Downs RW Jr, Lentle BC. Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry. J Clin Densitom. 2005;8:371-378. [EL 4; NE]
253. Bouxsein ML. Mechanisms of osteoporosis therapy: a bone strength perspective. Clin Cornerstone. 2003;Suppl 2:S13-S21. [EL 4; NE]
254. Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, et al. Early discontinuation of treatment for osteoporosis. Am J Med. 2003;115:209-216. [EL 3; survey SS]
255. Shen L, Xie X, Su Y, Luo C, Zhang C, Zeng B. Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials. PLoS One. 2011;6:e26267. [EL 1; MRCT]
256. Simon JA, Recknor C, Moffett AH Jr, Adachi JD, Franek E, Lewiecki EM, et al. Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. Menopause. 2013;20:130-137. [EL 1; RCT]
257. Schousboe JT, Vokes T, Broy SB, Ferrar L, McKiernan F, Roux C, et al. Vertebral Fracture Assessment: the 2007 ISCD Official Positions. J Clin Densitom. 2008;11:92-108. [EL 4; consensus NE]
258. Schousboe JT, Shepherd JA, Bilezikian JP, Baim S. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry. J Clin Densitom. 2013;16:455-466. [EL 4; consensus NE]
259. Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum. 1999;42:1246-1254. [EL 1; RCT]
260. Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom. 2004;7:255-261. [EL 1; MRCT]
261. Chapurlat RD, Palermo L, Ramsay P, Cummings SR. Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int. 2005;16:842-848. [EL 1; RCT]
262. Ryg J, Rejnmark L, Overgaard S, Brixen K, Vestergaard P. Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977-2001. J Bone Miner Res. 2009; 24:1299-1307. [EL 2; PCS]
263. Black DM, Arden NK, Palermo L, Pearson J, Cummings SR. Prevalent vertebral deformities predict hip fractures and new vertebral fractures but not wrist fractures. J Bone Miner Res. 1999;14:821-828. [EL 2; PCS]
264. Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH. Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab. 2005;90:1583-1587. [EL 1; RCT]
265. Lewiecki EM, Cummings SR, Cosman F. Treat-to-target for osteoporosis: Is now the time? J Clin Endocrinol Metab. 2013;98:946-953. [EL 4; opinion NE]
266. Cummings SR, Cosman F, Eastell R, Reid IR, Mehta M, Lewiecki EM. Goal-directed treatment of osteoporosis. J Bone Miner Res. 2013;28:433-438. [EL 4; opinion NE]
267. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753-761. [EL 4; review NE]
268. Bilezikian J. Osteonecrosis of the jaw: do bisphosphonates pose a risk? N Engl J Med. 2006;355:2278-2282. [EL 4; review NE]
269. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479-1491. [EL 4; consensus NE]
270. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30:3-23. [EL 4; review NE]
271. Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med. 2000;160:517-525. [EL 1; RCT]
272. Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2009;20:1353-1362. [EL 2; RCCS]
273. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29:1-23. [EL 4; review NE]
274. Watts N, Freedholm D, Daifotis A. The clinical tolerability profile of alendronate. Int J Clin Pract Suppl. 1999;101: 51-61. [EL 4; review NE]
275. de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996;335:1016-1021. [EL 3; CCS]
276. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25:2267-2294. [EL 4; review NE]
277. Kim SY, Schneeweiss S, Katz JN, Levin R, Solomon DH. Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. J Bone Miner Res. 2011;26:993-1001. [EL 2; PCS]
278. Sharma A, Chatterjee S, Arbab-Zadeh A, Goyal S, Lichstein E, Ghosh J, et al. Risk of serious atrial fibrillation and stroke with use of bisphosphonates: evidence from a meta-analysis. Chest. 2013;144:1311-1322. [EL 2; MNRCT]
279. Sharma A, Einstein AJ, Vallakati A, Arbab-Zadeh A, Walker MD, Mukherjee D, et al. Risk of atrial fibrillation with use of oral and intravenous bisphosphonates. Am J Cardiol. 2014;113:1815-1821. [EL 2; MNRCT]
280. Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res. 2010; 25:976-982. [EL 1; RCT]
281. Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, et al. The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2015;30:934-944. [EL 1; RCT]
282. Cosman F, Cauley JA, Eastell R, Boonen S, Palermo L, Reid IR, et al. Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? J Clin Endocrinol Metab. 2014;99:4546-4554. [EL 1; RCT]
283. Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31:16-35. [EL 4; consensus]
284. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27:243-254. [EL 1; RCT]
285. Russell RG. Bisphosphonates: the first 40 years. Bone. 2011;49:2-19. [EL 4; review]
286. Compston JE, Watts NB. Combination therapy for postmenopausal osteoporosis. Clin Endocrinol. 2002;56:565-569. [EL 4; review NE]
287. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349:1207-1215. [EL 1; RCT]
288. Cosman F, Eriksen EF, Recknor C, Miller PD, Guanabens N, Kasperk C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res. 2011;26:503-511. [EL 1; RCT, partial blinding]
289. Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SA, Zhu Y, Foley K, et al. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014;99:1694-1700. [EL 1; RCT]
290. Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015; 386:1147-1155. [EL 1; RCT]
291. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003;349:1216-1226. [EL 1; RCT]
292. Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, et al. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab. 2000; 85:2129-2134. [EL 1; RCT]
293. Diab DL, Watts NB. Postmenopausal osteoporosis. Curr Opin Endocrinol Diabetes Obes. 2013;20:501-509. [EL 4; review NE]
294. Leder BZ, Neer RM, Wyland JJ, Lee HW, Burnett-Bowie SM, Finkelstein JS. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J Clin Endocrinol Metab. 2009;94:2915-2921. [EL 2; PCS]
295. Kallmes DF, Comstock BA, Heagerty PJ, Turner JA, Wilson DJ, Diamond TH, et al. A randomized trial of vertebroplasty for osteoporotic spinal fractures. N Engl J Med. 2009;361:569-579. [EL 1; RCT]
296. Buchbinder R, Osborne RH, Ebeling PR, Wark JD, Mitchell P, Wriedt C, et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med. 2009;361:557-568. [EL 1; RCT]
297. Staples MP, Kallmes DF, Comstock BA, Jarvik JG, Osborne RH, Heagerty PJ, et al. Effectiveness of vertebroplasty using individual patient data from two randomised placebo controlled trials: meta-analysis. BMJ. 2011;343:d3952. [EL 1; MRCT, small sample size]
298. Kroon F, Staples M, Ebeling PR, Wark JD, Osborne RH, Mitchell PJ, et al. Two-year results of a randomized placebo-controlled trial of vertebroplasty for acute osteoporotic vertebral fractures. J Bone Miner Res. 2014;29: 1346-1355. [EL 1; RCT]
299. Blasco J, Martinez-Ferrer A, Macho J, San Roman L, Pomés J, Carrasco J, et al. Effect of vertebroplasty on pain relief, quality of life, and the incidence of new vertebral fractures: a 12-month randomized follow-up, controlled trial. J Bone Miner Res. 2012;27:1159-1166. [EL 1; RCT]
300. Klazen CA, Venmans A, de Vries J, van Rooij WJ, Jansen FH, Blonk MC, et al. Percutaneous vertebroplasty is not a risk factor for new osteoporotic compression fractures: results from VERTOS II. AJNR Am J Neuroradiol. 2010;31:1447-1450. [EL 1; RCT]
301. Bouza C, Lopez-Cuadrado T, Almendro N, Amate JM. Safety of balloon kyphoplasty in the treatment of osteoporotic vertebral compression fractures in Europe: a metaanalysis of randomized controlled trials. Eur Spine J. 2015;24:715-723. [EL 1; RCT]
302. Aghamirsalim M, Sorbi R. Do the hospitalized patients with osteoporotic fractures require endocrinologists' help? J Endocrinol Invest. 2012;35:992-995. [EL 3; SS]
303. Bell K, Strand H, Inder WJ. Effect of a dedicated osteoporosis health professional on screening and treatment in outpatients presenting with acute low trauma non-hip fracture: a systematic review. Arch Osteoporos. 2014;9:167. [EL 2; MNRCT]
304. Radonich M. Communicating radiation risk to the public. Presented at: Community Environmental Monitoring Program 25th Anniversary Annual Workshop; July 23-27, 2006; Mt. Charleston, NV. Available at: http://www.cemp.dri.edu/cemp/workshop2006/presentations/Radonich-Communicating_Radiation_Risk_to_the_Public-Part_1. pdf [EL 4; NE]
305. Edwards A, Elwyn G. How should effectiveness of risk communication to aid patients' decisions be judged? A review of the literature. Med Decis Making. 1999;19:428-434. [EL 4; review NE]
306. Lewiecki EM. 2011 The role of risk communication in the care of osteoporosis. Curr Osteoporos Rep. 2011;9:141-148 [EL 4; review NE]
307. Charles CA, Whelan T, Gafni A, Willan A, Farrell S. Shared treatment decision making: what does it mean to physicians? J Clin Oncol. 2003;21:932-936. [EL 3; SS]
308. Charles C, Gafni A, Whelan T. Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med. 1999;49:651-661. [EL 4; review NE]
309. Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med. 1997; 44:681-692. [EL 4; review NE]
310. Lewiecki EM. Risk communication and shared decision making in the care of patients with osteoporosis. J Clin Densitom. 2010;13:335-345. [EL 4; review NE]
311. Dowd R, Recker RR, Heaney RP. Study subjects and ordinary patients. Osteoporos Int. 2000;11:533-536. [EL 2; RCCS]
312. Trevena LJ, Davey HM, Barratt A, Butow P, Caldwell P. A systematic review on communicating with patients about evidence. J Eval Clin Pract. 2006;12:13-23. [EL 1; MRCT]
313. Boudreau JD, Cassell E, Fuks A. Preparing medical students to become attentive listeners. Med Teach. 2009;31: 22-29. [EL 4; review NE]
314. Hudson B, Toop L, Mangin D, Pearson J. Risk communication methods in hip fracture prevention: a randomised trial in primary care. Br J Gen Pract. 2011;61:e469-e476. [EL 1; RCT]
315. Montori VM, Shah ND, Pencille LJ, Branda ME, Van Houten HK, Swiglo BA, et al. Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial. Am J Med. 2011;124:549-556. [EL 1; RCT]
316. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89:1117-1123. [EL 1; RCT]
317. Briot K, Ravaud P, Dargent-Molina P, Zylberman M, Liu-Leage S, Roux C. Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int. 2009;20:625-630. [EL 2; PCS]
318. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011;364:1728-1737. [EL 2; RCCS]
319. Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int. 2001; 12:417-427. [EL 3; SS]
320. International Collaborative Study of Severe Anaphylaxis. Risk of anaphylaxis in a hospital population in relation to the use of various drugs: an international study. Pharmacoepidemiol Drug Saf. 2003;12:195-202. [EL 2; RCCS]
321. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: expert panel recommendations. J Am Dent Assoc. 2006;137:1144-1150. [EL 4; consensus recommendations]